EWTX Stock Price, Edgewise Therapeutics, . Quote, Chart

Market Summary

USD16.11+0.46

Market Closed

2.94%

EWTX Stock Price

View Fullscreen

EWTX RSI Chart

EWTX Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

-14.55

Price/Sales (Trailing)

104.14

Price/Free Cashflow

-14.92

EWTX Price/Sales (Trailing)

EWTX Profitability

Return on Equity

-31.42%

Return on Assets

-29.46%

Free Cashflow Yield

-6.7%

EWTX Fundamentals

EWTX Revenue

Revenue (TTM)

14.0M

Rev. Growth (Yr)

39.6%

Rev. Growth (Qtr)

-0.53%

EWTX Earnings

Earnings (TTM)

-100.2M

Earnings Growth (Yr)

-55.26%

Earnings Growth (Qtr)

-17.23%

Breaking Down EWTX Revenue

Last 7 days

-5.8%

Last 30 days

-3.6%

Last 90 days

2.2%

Trailing 12 Months

117.5%

How does EWTX drawdown profile look like?

EWTX Financial Health

Current Ratio

19.5

Debt/Equity

2e-4

Debt/Cashflow

-1.6K

EWTX Investor Care

Shares Dilution (1Y)

47.18%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	7.7M	11.0M	14.0M
2022	526.0K	843.0K	1.5M	4.0M
2021	48.0K	152.0K	278.0K	402.0K
2020	0	0	0	69.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Edgewise Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 09, 2024	derakhshan behrad	sold	-96,209	20.0436	-4,800	chief business officer
Feb 09, 2024	moore john r	acquired	15,496	1.93	8,029	general counsel
Feb 09, 2024	derakhshan behrad	acquired	9,264	1.93	4,800	chief business officer
Feb 09, 2024	moore john r	sold	-160,657	20.0096	-8,029	general counsel
Feb 08, 2024	derakhshan behrad	acquired	8,878	1.93	4,600	chief business officer
Feb 08, 2024	derakhshan behrad	sold	-92,048	20.0106	-4,600	chief business officer
Feb 08, 2024	moore john r	acquired	7,359	1.93	3,813	general counsel
Feb 08, 2024	moore john r	sold	-76,284	20.0065	-3,813	general counsel
Feb 07, 2024	derakhshan behrad	acquired	1,158	1.93	600	chief business officer
Feb 07, 2024	derakhshan behrad	sold	-12,000	20.00	-600	chief business officer

Which funds bought or sold EWTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	121,680	255,504	-%
Apr 19, 2024	DENALI ADVISORS LLC	new	-	350,208	350,208	0.10%
Apr 12, 2024	Financial Synergies Wealth Advisors, Inc.	new	-	2,025	2,025	-%
Apr 11, 2024	Fortitude Family Office, LLC	unchanged	-	1,168	2,918	-%
Apr 05, 2024	GAMMA Investing LLC	added	9.04	2,277	21,997	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	109	109	-%
Mar 11, 2024	VANGUARD GROUP INC	added	2.95	11,422,500	23,251,700	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	86.09	13,865,000	19,295,900	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	110,308	232,661	-%

Are Funds Buying or Selling EWTX?

Are funds buying EWTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EWTX

No. of Funds

Unveiling Edgewise Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	deep track capital, lp	4.00%	2,537,176	SC 13G/A
Feb 14, 2024	viking global investors lp	9.7%	6,159,146	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 07, 2024	blackrock inc.	4.1%	3,505,199	SC 13G/A
Feb 02, 2024	blackrock inc.	5.2%	3,307,110	SC 13G
Feb 01, 2024	flynn james e	0.64%	545,455	SC 13G/A
Jan 29, 2024	ra capital management, l.p.	9.6%	8,909,091	SC 13G
Jan 25, 2024	novo holdings a/s	7.4%	6,344,430	SC 13D/A
Jan 25, 2024	orbimed advisors llc	17.3%	14,756,096	SC 13D/A
Jun 28, 2023	novo holdings a/s	9.6%	6,071,703	SC 13D/A

Recent SEC filings of Edgewise Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	PRE 14A	PRE 14A
Feb 22, 2024	10-K	Annual Report
Feb 22, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 09, 2024	4	Insider Trading
Feb 09, 2024	4	Insider Trading
Feb 09, 2024	SC 13G/A	Major Ownership Report
Feb 07, 2024	144	Notice of Insider Sale Intent
Feb 07, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Edgewise Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

Edgewise Therapeutics, Inc. News

Latest updates

Edgewise Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	-0.5%	3,719	3,739	3,870	2,664	764	424	166	126	127	107	42.00	2.00	1.00	3.00	63.00
Operating Expenses	15.0%	33,862	29,452	25,339	22,079	18,262	16,491	14,826	12,822	13,076	10,460	6,857	6,344	3,643	3,957	3,248
S&GA Expenses	9.0%	6,178	5,666	5,780	5,467	4,368	4,089	3,702	3,734	3,196	2,599	1,497	1,205	405	318	281
R&D Expenses	16.4%	27,684	23,786	19,559	16,612	13,894	12,402	11,124	9,088	9,880	7,861	5,360	5,139	3,238	3,639	2,967
Net Income	-17.2%	-30,143	-25,713	-21,469	-19,415	-17,498	-16,067	-14,660	-12,696	-12,949	-10,353	-6,815	-6,342	-3,642	-3,954	-3,185
Net Income Margin	11.7%	-7.16*	-8.10*	-8.92*	-16.83*	-19.56*	-25.51*	-38.79*	-106.50*	-131.15*	-178.63*	-432.35*	-248.16*	-	-	-
Free Cashflow	-19.9%	-26,991	-22,515	-20,993	-15,148	-13,293	-16,799	-12,941	-9,498	-8,713	-9,845	-6,119	-4,638	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	9.2%	340	311	331	346	367	377	257	273	285	294	303	311	131
Current Assets	9.8%	327	298	317	333	357	370	253	269	284	293	303	311	130
Cash Equivalents	161.2%	86.00	33.00	32.00	48.00	22.00	110	18.00	34.00	16.00	11.00	50.00	221	105
Net PPE	-2.2%	10.00	11.00	11.00	10.00	9.00	5.00	2.00	1.00	1.00	1.00	1.00	0.00	1.00
Liabilities	1.3%	21.00	21.00	19.00	18.00	20.00	16.00	11.00	12.00	11.00	9.00	-	-	4.00
Current Liabilities	2.7%	17.00	16.00	14.00	13.00	17.00	13.00	9.00	10.00	11.00	9.00	7.00	5.00	4.00
Short Term Borrowings	-	-	-	-	-	-	0.00	-	-	-	-	-	-	-
Long Term Debt	-	-	-	-	-	-	0.00	-	-	-	-	-	-	-
Shareholder's Equity	9.8%	319	290	311	329	347	361	246	260	274	285	297	306	-
Retained Earnings	-14.0%	-244	-214	-188	-167	-144	-125	-107	-91.62	-76.96	-64.30	-51.30	-41.00	-34.15
Additional Paid-In Capital	11.5%	563	505	501	497	493	489	356	354	352	350	348	347	1.00
Accumulated Depreciation	-	-	-	-	-	-	-	1.00	1.00	1.00	1.00	1.00	1.00	0.00
Shares Outstanding	11.0%	70.00	63.00	63.00	63.00	63.00	52.00	50.00	50.00	50.00	49.00	26.00	-	-
Float	-	-	-	386	-	-	-	248	-	-	-	653	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-21.6%	-26,830	-22,058	-20,234	-22,826	-11,855	-11,963	-16,245	-12,572	-9,419	-8,262	-9,769	-6,057	-4,638	-3,272	-3,985	-2,739
Share Based Compensation	13.0%	5,153	4,559	4,011	3,837	3,736	3,173	2,037	1,978	1,873	1,548	687	296	190	70.00	49.00	45.00
Cashflow From Investing	15.2%	26,983	23,419	3,442	49,042	-75,596	-26,321	-46.00	31,386	14,121	-31,608	-159,967	-64,773	-24,178	-6.00	-188	-9.00
Cashflow From Financing	25212.3%	52,987	-211	369	21.00	-303	129,690	179	73.00	293	37.00	-896	186,950	-	-	-	-

EWTX Income Statement

2023-12-31

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses
Research and development	$ 90,905	$ 54,032
General and administrative	23,452	17,626
Total operating expenses	114,357	71,658
Loss from operations	(114,357)	(71,658)
Other income
Interest income	14,194	4,018
Total other income	14,194	4,018
Net loss	(100,163)	(67,640)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities	1,454	(841)
Total comprehensive loss	$ (98,709)	$ (68,481)
Net loss per share, basic (in dollars per share)	$ (1.57)	$ (1.26)
Net loss per share, diluted (in dollars per share)	$ (1.57)	$ (1.26)
Weighted-average shares outstanding, basic	63,723,600	53,593,753
Weighted-average shares outstanding, diluted	63,723,600	53,593,753

EWTX Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 86,097	$ 21,993
Marketable securities, available for sale	232,296	329,954
Prepaid expenses and other assets	8,604	5,052
Total current assets	326,997	356,999
Property and equipment, net	10,443	8,533
Operating lease right-of-use asset	2,247	1,318
Other non-current assets	348	251
Total assets	340,035	367,101
Current liabilities
Accounts payable	4,025	6,105
Accrued compensation	5,695	4,032
Accrued other expenses	6,071	5,840
Operating lease liability, current portion	980	608
Total current liabilities	16,771	16,585
Operating lease liability, net of current portion	4,434	3,800
Total liabilities	21,205	20,385
Commitments and contingencies (see note 5)
Stockholders' equity:
Preferred stock, $.0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of December 31, 2023 and December 31, 2022
Common stock, $.0001 par value per share; 1,000,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 70,453,342 shares and 63,257,376 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	7	6
Additional paid-in capital	563,487	492,665
Accumulated other comprehensive income (loss)	99	(1,355)
Accumulated deficit	(244,763)	(144,600)
Total stockholders' equity	318,830	346,716
Total liabilities and stockholders' equity	$ 340,035	$ 367,101

About Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The Company was incorporated in 2017 and is headquartered in Boulder, Colorado.

CEO	Dr. Kevin Koch Ph.D.
WEBSITE	edgewisetx.com
INDUSTRY	Biotechnology
EMPLOYEES	74

Edgewise Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Edgewise Therapeutics, Inc.? What does EWTX stand for in stocks?

EWTX is the stock ticker symbol of Edgewise Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Edgewise Therapeutics, Inc. (EWTX)?

As of Tue Apr 23 2024, market cap of Edgewise Therapeutics, Inc. is 1.46 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EWTX stock?

You can check EWTX's fair value in chart for subscribers.

What is the fair value of EWTX stock?

You can check EWTX's fair value in chart for subscribers. The fair value of Edgewise Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Edgewise Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EWTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Edgewise Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether EWTX is over valued or under valued. Whether Edgewise Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Edgewise Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EWTX.

What is Edgewise Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, EWTX's PE ratio (Price to Earnings) is -14.55 and Price to Sales (PS) ratio is 104.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EWTX PE ratio will change depending on the future growth rate expectations of investors.